PSA Chemistry Approaches: Acrylic, Silicone, Rubber-Based, and Hybrid Formulations

Pressure-sensitive adhesive materials for electronics and medical devices are built on four dominant chemistry platforms — acrylic, silicone, rubber-based, and hybrid formulations — each engineered to address distinct combinations of substrate compatibility, environmental durability, and regulatory compliance. The choice of chemistry is rarely arbitrary: it is driven by the specific mechanical and chemical demands of the end application, whether that is bonding a flex circuit in a smartphone assembly or maintaining skin contact on a wearable cardiac monitor over multiple days.

Acrylic PSAs are the most widely deployed chemistry across both industries. Their versatility stems from the ease with which monomer composition can be tuned to adjust tack, peel strength, and shear resistance. In electronics manufacturing, acrylic formulations are favoured for optical clear adhesive (OCA) applications in display lamination, where optical transparency and minimal haze are non-negotiable. In medical contexts, acrylic PSAs are common in skin-contact products such as wound-care dressings and continuous glucose monitor patches, where a balance of gentle adhesion and moisture-vapour transmission is required.

Silicone PSAs occupy a distinct performance tier. Their inherent thermal stability — maintaining adhesive function across a wide temperature range — makes them indispensable for electronics assemblies subject to reflow soldering or high-temperature operational environments. In medical devices, silicone chemistry is preferred for sensitive-skin applications and for adhesives that must remain functional through sterilisation cycles, including gamma irradiation and ethylene oxide (EtO) processing. Silicone PSAs also exhibit low extractables, which is advantageous for implantable or long-term skin-contact applications where leachable compounds are a regulatory concern.

Rubber-based PSAs — both natural and synthetic rubber systems — offer high initial tack and cost efficiency, making them a practical choice for high-volume electronics assembly tapes, EMI shielding tape systems, and general-purpose die-attach films. However, their comparatively limited thermal and UV stability restricts their use in demanding long-term applications. Hybrid formulations, which blend acrylic and silicone chemistries or incorporate block copolymer architectures, are an active area of development, targeting applications where neither pure chemistry alone delivers the required combination of properties — for example, a medical wearable that must adhere gently to skin for seven days while also withstanding brief exposure to water and topical agents.

Application Domains: From Die-Attach Films to Wearable Medical Sensors

Pressure-sensitive adhesive materials serve distinct and technically demanding roles across at least five major application domains spanning electronics and medical device manufacturing. Each domain imposes a unique set of performance requirements that determine which PSA chemistry and construction is appropriate, and where the boundaries of current material capability lie.

Electronics Application Domains

In electronics manufacturing, die-attach films represent one of the most demanding PSA applications. These thin adhesive layers must bond semiconductor dies to substrates or lead frames with sufficient mechanical strength to survive wire bonding, encapsulation, and thermal cycling, while maintaining low ionic contamination to protect device reliability. Outgassing is a critical parameter: volatile species released from the adhesive during processing or operation can contaminate optical surfaces or degrade electrical contacts.

Optical clear adhesives (OCA) for display lamination are a high-growth segment. As consumer electronics displays move toward thinner form factors and flexible substrates, OCA formulations must deliver high optical transmission, low haze, and reliable adhesion to glass, polyimide, and cover lens materials across a wide temperature range. EMI shielding tape systems represent another significant electronics domain, where conductive PSA constructions must provide consistent electrical contact to grounding points while withstanding the mechanical stresses of assembly and field use.

Medical Device Application Domains

Medical-grade PSA applications centre on skin-contact interfaces, wound care, and implantable or semi-implantable device mounting. Wearable medical sensors — including continuous glucose monitors, cardiac rhythm monitors, and drug delivery patches — require adhesives that can maintain reliable skin contact for extended wear periods (commonly one to fourteen days) without causing skin irritation, maceration, or allergic sensitisation. Release-liner engineering is integral to this category: the liner must protect the adhesive during storage and allow clean, consistent removal at the point of application without delaminating the adhesive from the device substrate.

Wound-care dressings represent a high-volume medical PSA segment, where the adhesive must balance sufficient peel strength to secure the dressing during wear with atraumatic removal that does not damage fragile or healing skin. Implantable device interfaces present the most stringent requirements: adhesives in this category must demonstrate long-term stability in a physiological environment, resist enzymatic degradation, and pass rigorous biocompatibility testing under ISO 10993.

Regulatory and Biocompatibility Engineering in Medical-Grade PSAs

Medical-grade PSA materials face a regulatory environment that is fundamentally more demanding than electronics applications, requiring systematic biocompatibility evaluation and, in many cases, adhesive reformulation to satisfy evolving market access requirements. The central standard governing biocompatibility assessment is ISO 10993 — a multi-part series published by the International Organization for Standardization that defines the framework for evaluating the biological safety of medical devices, including their adhesive components.

“Medical-grade PSA formulations must pass ISO 10993 cytotoxicity testing and demonstrate sterilisation compatibility — requirements that drive fundamental reformulation decisions distinct from electronics-grade adhesive engineering.”

ISO 10993 compliance for PSA materials encompasses cytotoxicity testing (Part 5), sensitisation assessment (Part 10), and irritation or skin sensitisation evaluation (Part 23 for skin-contact devices). For adhesives intended for implantable applications, additional testing under Parts 6 and 11 — addressing local effects after implantation and systemic toxicity — is required. The extractables and leachables profile of the adhesive chemistry is therefore a critical design parameter: silicone and certain acrylic formulations are favoured partly because their extractables can be characterised and controlled within acceptable thresholds.

The EU Medical Device Regulation (EU MDR), which entered full application in 2021 and continues to shape device development pipelines in 2026, has elevated the scrutiny applied to all device components — including adhesives — by requiring more comprehensive technical documentation and, for higher-risk devices, clinical evidence of safety and performance. This has prompted manufacturers to audit PSA chemistries that were previously grandfathered under the older Medical Device Directive (MDD) and to reformulate where extractables profiles or cytotoxicity data are insufficient under the new standard.

Sterilisation compatibility is a further reformulation driver. PSA materials used on devices that are terminally sterilised must retain their adhesive properties — peel strength, tack, and substrate bond integrity — after exposure to the sterilisation method specified for the device. Gamma irradiation, the most common terminal sterilisation method for disposable medical devices, can degrade certain acrylic and rubber-based PSA chemistries through chain scission or crosslink density changes, altering adhesive performance. Silicone PSAs, by contrast, are generally more radiation-stable, which is one reason they are disproportionately represented in implantable and terminally sterilised device applications. Standards bodies including ISO and the FDA provide guidance on validating sterilisation processes for medical device components.

Key Players and IP Positioning in the PSA Materials Landscape

Assignee concentration in the PSA materials patent landscape for electronics and medical devices is high, with a small number of specialty materials and diversified industrial companies accounting for a disproportionate share of historical filing activity. Based on filing frequency in this domain, the leading assignees are 3M, Nitto Denko, Avery Dennison, Henkel, Lohmann, and tesa SE — firms whose portfolios span both electronics and medical device PSA applications.

3M’s PSA portfolio is among the broadest, covering acrylic, silicone, and hybrid chemistries across medical, electronics, and industrial applications. The company’s medical division has historically been a major filer in skin-contact adhesive and wound-care dressing technologies, while its electronics division has contributed substantially to OCA and EMI shielding tape IP. Nitto Denko, headquartered in Japan, holds significant positions in optical adhesive films and flexible electronics bonding, reflecting the company’s deep integration with the Asian consumer electronics supply chain. According to WIPO, Japan remains one of the most active jurisdictions for PSA-related patent filings globally.

Avery Dennison’s IP positioning centres on label and tape constructions, with a notable presence in medical-grade skin-contact adhesives and release-liner systems. Henkel — through its Loctite and Bostik brands — holds positions in structural and semi-structural adhesive systems that overlap with PSA territory in flex circuit and die-attach applications. Lohmann and tesa SE (a Beiersdorf subsidiary) both maintain focused portfolios in specialty tape constructions for medical and electronics markets, with tesa SE particularly active in double-sided tape systems for display assembly.

The competitive IP landscape is characterised by layered patent thickets around core PSA chemistries, with differentiation increasingly occurring at the level of construction engineering — coating weight, liner selection, and multi-layer laminate architecture — rather than base polymer chemistry. This creates both freedom-to-operate challenges for new entrants and opportunities for innovation in application-specific constructions that may not be captured by existing claims. Patent databases maintained by the EPO and USPTO provide searchable access to the full scope of published PSA patent activity.

Electronics-Grade vs. Medical-Grade PSA: Performance Trade-Offs

Electronics-grade and medical-grade PSA materials share a common functional principle — adhesion under light pressure without requiring a liquid adhesive or activation step — but diverge substantially in their performance priorities, test methods, and qualification requirements. Understanding these trade-offs is essential for engineers and procurement professionals navigating dual-use applications or seeking to transfer material solutions between sectors.

Electronics-grade PSAs are optimised primarily for peel strength consistency, low outgassing, chemical resistance to process solvents and fluxes, and dimensional stability under thermal cycling. Outgassing is measured by methods such as ASTM E595, which quantifies total mass loss and collected volatile condensable material under vacuum and elevated temperature — parameters that directly affect optical surfaces and electrical contacts in assembled electronics. Chemical resistance is evaluated against the specific process chemicals used in the manufacturing environment, which can include isopropyl alcohol, acetone, and flux residues.

Medical-grade PSAs, by contrast, are evaluated against a biocompatibility framework where the primary concern is the biological response of the patient — not the chemical environment of a manufacturing line. Peel strength must be sufficient to maintain device positioning during wear, but must also be controlled to avoid skin trauma on removal, particularly for elderly or fragile-skin patients. Moisture-vapour transmission rate (MVTR) is a critical parameter for skin-contact adhesives: insufficient MVTR leads to occlusion and maceration of the skin beneath the device, increasing the risk of skin breakdown and infection in long-wear applications.

“In electronics-grade PSAs, the dominant qualification metric is outgassing; in medical-grade PSAs, it is biocompatibility and atraumatic removal — two entirely different engineering objectives that drive distinct formulation strategies.”

Sterilisation compatibility, as discussed in the regulatory section, introduces a further dimension of divergence. An electronics-grade acrylic PSA optimised for low outgassing may fail biocompatibility testing due to residual monomers or photoinitiator fragments. Conversely, a silicone PSA formulated for implantable device use may not provide the peel strength consistency or chemical resistance required for an electronics assembly tape application. Hybrid formulations that attempt to bridge these requirements are technically feasible but represent a more complex development and qualification pathway, requiring both electronics process validation and ISO 10993 biocompatibility testing. The PatSnap R&D Intelligence platform enables materials scientists to map these requirement intersections against the existing patent landscape, identifying prior art and white-space opportunities simultaneously. For broader context on materials testing standards, the PatSnap resources library provides additional guidance on navigating regulatory and IP considerations in advanced materials development.